i Summary A series of novel 3,4-dihYdro-6~/Jenzyl-4-oxop~~imi dines substituted at both the Ci~~nd the C-2 positions were synthesized as potential anti-HIV agents. Preparation of the title compounds was achieved by condensation of O-methylisourea with methyl 2-alkyl-4-phenylacetylacetate and subsequent displacement of the methoxy group by reaction with a series of linear, ramified and cyclic alkoxy groups containing from three to six carbon units. MethyI2-alkyl-4-phenylacetylacetates were prepared by alkylation of methyl 4-phenylacetylacetate, which was obtained starting from Meldrum's acid and phenacetyl chloride. Acid hydrolysis of 3,4-dihydro-6-benzyl-2-methoXY-4oxopyrimidines furnished the corresponding 1,2,3,4tetrahydro-6-benzyl-2,4-dioxopyrimidines. In acutely infected MT-4 cells, compounds 3e, 30, 3q and 3r showed an anti-HIV-1 activity as potent and/or selective as HEPT and ddl. Unlike HEPT, the replacement of a methyl for an hydrogen atom at position C-5 of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (OABOs)did not abolish the antiviral activity, as well as the substitution ofthe C-5 methyl for an ethyl group did not increase the potency. However, similarly to HEPT and its derivatives, OABOs targeted the HIV-1 reverse transcriptase and neither inhibited the multiplication of HIV-2 in acutely infected MT-4 cells, nor that of HIV-1 in chronically infected H9/IIIB cells.
Introduction
The advent of AIDS and the identification of human retroviruses, human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2), as the causative agents of this disease (Barre-Sinoussi et aI., 1983; Gallo et aI., 1984; Clavel et al., 1986) have led to efforts aimed at developing an effective chemotherapy. To this end the HIV reverse transcriptase (Rn, which is required for early proviral DNA synthesis, has been a primary target.
The first compounds proven to inhibit potently and selectively this enzyme have been nucleoside analogues. Among them are the three drugs approved for clinical use: 3' -azido-3'-deoxythymidine (azidothymidine, zidovudine, AZn (Mitsuya et al., 1985) , 2',3'-dideoxycytidine (ddC) (Mitsuya and Broder, 1986 ) and 2',3'-dideoxyinosine (ddl) (Yarchoan et al., 1989) , which act as chain terminators.
More recently, new RT inhibitors have been developed (Miyasaka et aI., 1989; Merluzzi et al., 1990; Kukla et al., 1991; Romero etal., 1991) . UnlikeAZT, ddC and ddl, these compounds affect the reverse transcription by interacting with an RT site other than the dXTP site, and show high potency and selectivity against HIV-1, but not against HIV-2 or other animal retroviruses (Baba et el., 1991; Debyser et al., 1991; Wu etal., 1991) .
Among these new RT inhibitors, HEPT (1a) and one of its analogues, compound 1b are relevant to the present study (Miyasaka et aI., 1989; Tanaka et aI., 1991) . In a search for new potential dihydrofolate reductase inhibitors, we have recently synthesized several 6-benzylpyrimidines whose structural similarity with the HEPT analogue 1b suggested that it may be useful to test them also for anti-HIV activity. Compound 2 and some related derivatives have been shown to be selective, although not very potent, HIV-1 inhibitors (Botta etal., 1992) .
When compared to 1b, compound 2 differed by the absence of both a (2-hydroxyethoxy)methyl substituent at the N-1 position and a methyl group at the C-5 position, and by the presence of a butoxy group at the C-2 position of the pyrimidine ring. This peculiar feature, and the fact that the anti-Hlv-t activity of HEPT and analogues depends on a substituent (methyl, ethyl, iso-propyl) at the C-5 position of the pyrimidine ring (Tanaka et aI., 1992) , have prompted us to synthesize and to investigate as potential anti-HIV agents various new 3,4-dihydro-2alkoxy-6-benzyl-4-oxopyrimidines (DABOs) 3 and some 1,2,3,4-tetrahydro-6-benzyl-2,4-dioxopyrimidines 4 ( Fig.  1) .
Chemistry
Methyl4-phenylacetylacetate 5a was prepared according to a method described previously (Oikawa et al., 1990) starting from 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) and phenylacetyl chloride. Treatment of the above ester with ethyl iodide in the presence of sodium methoxide afforded methyI2-ethyl-4-phenylacetylacetate 5c. The known methyI2-methyl-4-phenylacetylacetate 5b (Zajaczkowska-Terpinoska and Bisanz, 1975) was prepared according to the same procedure (Fig. 2) .
Condensation between O-methylisourea sulphate and methyl 4-phenylacetylacetate or its 2-methyl and 2-ethyl derivatives furnished 3,4-dihydro-6-benzyl-2-methoxy-4oxopyrimidine 3a (R = H) or its 5-alkyl derivatives 3k (R = Me) and 3s (R = Et), respectively. Reaction of 3a,k,s with the appropriate sodium or potassium alkoxide afforded the required 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines 3b-j,l-r,t-v whereas hydrolysis of 3a,k gave the related 1,2,3,4-tetrahydro-6-benzyl-2,4-dioxopyrimidines 4a,b (Fig. 3 ). OMe R derivatives were devoid of anti-HIV-1 activity and a comparison between the EC so values of derivatives 3d and 3j showed that the hydroxyl function contributes strongly to ablating the anti-HIV-1 activity of 3d. When different DABOs effective against HIV-1 were examined for inhibition of HIV-2-induced cytopathogenicity in acutely infected MT-4 cells (Table 2) , none was found active at doses up to 200 f.LM. This indicated that DABOs discriminate between HIV-1 and HIV-2. Moreover, the above compounds were ineffective in reducing the HIV-1 yield in chronically infected H9/IIIB cells (Table 2) , a finding that suggested an interference of DABOs with a phase of the HIV-1 replication cycle preceding provirus integration.
Therefore, compounds 3e, 3q and 3r were evaluated for inhibition of RNA-dependent DNA polymerase associated activity of the HIV-1 rRT(Table3). The IC so values obtained for the three DABOs were closely related to the ECso values observed for HIV-1 multiplication in MT-4 cells, and were 5-1 0 fold lower than the HEPT's IC so value. When the same DABOs were evaluated against the HIV-2 rRT, no inhibition was found at concentrations up to 100 f.LM (results not shown). 
Results
The cytotoxicity and anti-HIV-1 activity of the 24 newly synthesized compounds in MT-4 cells are shown in Table  1 , together with those obtained with 2' ,3'-dideoxyinosine (ddl). Also shown are the data obtained for HEPT (1 a) and its analogue 1b under similar assay conditions by Tanaka eta!. (1991) .
Most of the DABO derivatives were selective inhibitors of HIV-1 induced cytopathogenicity in MT-4 cells. The maximum inhibitory potency was obtained with secbutoxy (3e, 30) and cycloalkoxy (3q, 3r) derivatives, which appeared to be anti-HIV-1 agents superior to 1b and as potent and/or selective as 1a (HEP1) and ddl. On the contrary, 2-oxo (4a, 4b) and 2-methoxy (3a, 3k, 35) R = H, Me, Et R' = a-alkyl. i-alkyl, cycloalky! 
Discussion
Efforts aimed at developing new anti-HIV compounds have led to the discovery of structurally unrelated classes of RT inhibitors such as HEPT, TIBO, BHAP, nevirapine. Each of these compounds, generally referred to as nonnucleoside reverse transcriptase inhibitors, presents peculiar patterns of interaction with the HIV-1 RT (Baba et aI., 1991; Oebyser et aI., 1991; Tramontano and Cheng, 1992 ) indicating a mode of action different from that of classical nucleoside analogues. The data presented here disclose a new class of specific inhibitors of HIV-1 multiplication in acutely infected cells, the OABOs (3), which also specifically inhibit the HIV-1 rRT.
Although OABOs share some structural features with compounds belonging to the HEPTclass (i.e, the oxopyrimidine instead of the dioxopyrimidine moiety and the benzyl chain which replaces the bioisosteric phenylthio portion at the C-6 position), they are characterized by an alkoxy side chain linked at the C-2 position of the pyrimidine ring, whereas HEPT derivatives possess a substituent linked at the N~1 position mimicking an acyclic sugar. Thus, when 4b, 1b and 31-r are compared, it appears that anti-HIV-1 activity can be conferred to 4b by properly substituting either the N-1 or the C-2 position.
Synthetic studies on HEPT analogues have so far suggested that their anti-HIV-1 activity depends on the Table 2 . Effect of DABO derivatives against the multiplication of HIV-2 in acutely infected MT-4 cells. and of HIV-1 in chronically infected H9/IIIB cells.
HIV-2
HIV-1
a Effective concentration (f.LM) of compound required to achieve 50% protection of MT-4 cells against the cytophatic effect of HIV-2. b Effective concentration (f.LM) of compound required to reduce the yield of HIV-1 by 90%.
C Data taken from Baba et st. (1989) . Tramontano and Cheng (1992) .
presence of a methyl, ethyl or iso-propyl substituent at the C-5 position ofthe pyrimidine ring (Tanaka et et., 1992) . On the contrary, the anti-HIV-1 activity of DABOs essentially depends on the appropriate size of the C-2 alkoxy chain (compare 3a, 3k, 3s with 3b-h, 31-r and 3t-v). In fact, unlike HEPT, in which the replacement of the C-5 methyl group by an hydrogen atom results in total loss of activity , most of the C-5 H-substituted
DABOs retained an antiviral activity comparable to that of tne C-5 methyl substituted counterparts. The sole exception was compound 3q, which was four times more potent and less than half as toxic as 39 (cf. CC so and EC so of 3q and 39 in Table 1 ). Moreover, the DABO derivatives studied showed a lack of consistent increase in potency following the substitution of the C-5 methyl for an ethyl group, a substitution which enhanced the potency of HEPT derivatives (Tanaka et sl., 1991) .
In conclusion, DABO derivatives can be considered a new class of specific inhibitors of the HIV-1 multiplication in acutely infected cells, targeting the HIV-1 RT. These compounds are being further pursued to evaluate the extent of structural and/or biological similarities with HEPT derivatives and other non-nucleoside RT inhibitors.
Materials and Experimental procedures

Chemistry
Melting points were taken on a Buehl 530 apparatus and are uncorrected. IR spectra (Nujol mulls) were run on a Perkin-Elmer 298 spectrophotometer. 1H NMR spectra (TMS as an internal standard) were recorded on a Varian EM 360 instrument. Merck silica gel 60 was used for chromatographic purifications. All compounds were routinely checked by TLC and 1H NMR. Thin layer chromatography (TLC) was performed by using aluminium baked silica gel plates (Carlo Erba Stratocrom SIF-254) and EtOAc/CHCI 3 1:1 as eluent. Developed plates were visualized by UV light. Solvents were reagent grade and when necessary (xylene for preparation of some derivatives 3) were purified and dried by standard methods. All the alcohols used needed a preliminary anhydrification. Concentration of solutions after reactions and extractions involved use of a rotary evaporator operating at reduced pressure of approximately 20 torr. Organic solutions were dried over anhydrous Na2S04'Elementalanalyses were performed by Professor A. Pietrogrande, Padova, Italy. All compounds were analysed for C, H, N and analysis values were within ±0.4% of the theory.
MethyI2-ethyl-4-phenylacetoacetate (Sc)
Anhydrous pyridine (400mmoles, 32.5ml)was added with stirring under nitrogen atmosphere into an ice-cooled solution of 2,2dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) (165 mmoles, 23.75g) in anhydrous CH 2CI2 (65ml). The resulting solution was treated with a solution of freshly distilled phenylacetyl chloride (160 mmoles, 25.0g) in anhydrous CH 2Cl 2 (50ml) over a 2 h period. After adding the mixture was stirred for 2 h at room temperature, then poured into crushed ice and treated with 2N HCI (100ml). The organic layer was separated and aqueous solution extracted twice with CH 2CI2 (25ml). The organic phase and the extracts were combined, washed with brine, dried, and evaporated. The solid residue was dissolved in anhydrous CH 30H (250ml) and the solution was refluxed for 20h. After cooling, Na (0.16g-atoms, 3.68g) was carefully added and the mixture was stirred until dissolution of metal was complete. Etl (160 mmoles, 12.9ml) was dropped into the solution and the resulting mixture was heated at reflux for 4h. After cooling, the solvent was removed and the residue treated with H 20 (200ml) and extracted with CHCI 3 (3 x 100ml). The organic layer was washed with brine (2 x 100ml), dried and evaporated to give a residue, which was purified by passing through a silica gel column (CHCb as eluent).Pure5c (16.5g, 47%) was obtained as a yellow oil; IR (cm-1) 1710 (CO) and 1740 (COOEt); 1HNMR (CCI 4) s 0.80 (t, 3H, CH2CHS), 1.70-1.93 (m, 2H, CH 2CH3 ) , 3.10-3.40 (m, 1H, CH), 3.60 (s, 3H, OCH 3), 3.70 (s, 2H, CH 2Ph), 7.00-7.30 (m, 5H, Ph). Anal. (C13H160S) C, H.
General procedure for the preparation of derivatives 3a,k,s
To a well-stirred suspension of O-methylisourea hydrogen sulphate (15 mmoles) and Ca(OHh (3k, 3s) or Na2C03 (3a) (16 mmoles) in water (50ml),the proper l3-ketoester5 (10 mmoles) in CH30H (50ml) was added. The resulting mixture was stirred at room temperature for 72h, then concentrated, made acid (pH 5) with O.5N AcOH and extracted with EtOAc (3 x 50ml). The combined organic extracts were washed with brine (100ml), dried, and evaporated to dryness. The residue was purified by crystallization from the proper solvent (a preliminary purification by silica gel column chromatography (EtOAc/CHCI 3 1:1 as eluent) was needed for 3s). Characteristic data for derivatives 3a,k,s are reported in succession. General procedure for the preparation of derivatives 3b-j,I-r, t-v Metal (Na or K) in small pieces was carefully added with stirring to the proper alcohol freshly distilled on Na. In some cases adding of dry (P 20S ) xylene as solvent was required.to ameliorate the yield of the reaction. Dissolution of metal was completed by heating at 70-80°C, then 2-methoxy-6-benzyl-4-pyrimidinone 3 (a,k or s) was added and the mixture was heated at reflux under nitrogen atmosphere. The reaction was stopped when starting material 3 was absent at the TLC control. After coSling, the mixture was concentrated, made acid (pH 5) with OJlfJ AcOH and extracted with EtOAc (3 x 50 ml). The combined extracts were washed once with brine (100ml), dried and evaporated to give the required" derivative 3, which was recrystallized from suitable solvent (some compounds required a preliminary purification by column chromatography). Characteristic data for each compound are reported as follows: A: alcohol (mmoles or ml); B:.solvent (ml); C: 
Compound 3d
A: 1-hydroxybutane (50 ml); C: Na (0.1); 0: 3a (10); E: 48; G: 67; H: EtOAc; I: 124-125; J: C1sH1SN202 (258.32); K: 1635, 3280; L: (CDCb) 0.92 (t, J = 6.5 Hz, 3H, CH s), 1.25-1.77 (m, 4H, CH 2hCH s), 3.75 (5, 2H, CH 2Ph), 4.37 (t, J = 6.5Hz, 2H, OCH 2); 5.87 (5, 1H, 5-H), 7.27-7.37 (rn, 5H, Ph).
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Compound3e A: 2-hydroxybutane (50ml); C: K (0.1); 0: 3a (10); E: 72; G: 56; H: n-hexane; I: 93-94; J: C1sH1SN202 (258.32); K: 1640,3330; L: (CDCb) 0.90 (t, J = 7.0Hz,3H, CH 2CHs ), 1.27 (d,J = 7.0Hz,3H, CHCH s ), 1.47-1.83 (m, 2H, CH 2CHs ), 3.72 (5, 2H, CH 2Ph), 5.13 (q, J = 7.0Hz, 1H, OCH); 5.83 (s, 1H, 5-H), 7.27-7.33 (m, 5H, Ph). L: (CDCl s) 1. 4H, 3 and 4 tetrahydrofuryl), 2H, 5 tetrahydrofuryl), 3.72 (5, 2H, CH 2Ph overlapped signal), 3H, 5.85 (5, 1H, 5H, Ph) . L: (CDCb) 1.55-1.83 (rn, 4H, OCH 2-(CH2hCH20H), 3.63 (t, J = 6.0 Hz, 2H, CH 2 0 H), 3.72 (5, 2H, CH 2Ph), 4.37 (t, J = 6.0 Hz, 2H, OCH 2), 5.83 (5, 1H, 5H, Ph) .
Compound 31
A: 1-hydroxypropane (50ml); C: K (0.1); 0: 3k (10); E: 96; G: 54; H: cyclohexane; I: 128-129; J: C1sH1SN202 (258.32); K: 1635, 3340; L: (CDCl s) 0.93 (t, J = 7.0Hz, 3H, CH 2CHs), 1.72(q, J = 7.0 Hz, 2H, CH 2CH3), 2.03 (s, 3H, 5-Me), 3.85 (s, 2H, CH2Ph), 4.1 0 (t, J = 7.0Hz, 2H, OCH 2), 7. 5H, Ph) .
Compound 3m
A: 2-hydroxypropane (50ml); C: K (0.1); D: 3k (10) 
Compound3t
A: 1-hydroxypropane (50 ml); C: K (0.1); D: 35 (10); E: 240; F: 8i0 2, EtOAc/CHCI 3 1:1; G: 53; H: n-hexane; I: 91-93; J: C1sH20N202 (272.34); K: 1635,3330; L: (CDCI 3 ) 0.92 (t, 3H, (CH 2l2CH3 ) , 1.05 (t, 3H, 5-CH 2CH3), 1.72 (q, 2H, CH 2CH2-CH 3 ) , 2.55 (q, 2H, 5-CH2CH 3), 3.85 (s, 2H, CH 2Ph), 4.25 (t, 2H, OCH 2), 7.23-7.33 (rn, 5H, Ph).
Compound3u
A: 2-hydroxypropane (50 ml); C: K (0.1); D: 35 (10); E: 120; F: 8i0 2, EtOAc/CHCb 1:1; G: 42; H: cyclohexane; I: 128-131; J: C 1sH20 N 202 (272.34); K: 1640, 3330; L: (CDCI 3 ) 1.03 (t, J = 8.0 Hz, 3H, 5-CH 2CH3), 1.23 (d, 6H, CH(CH 3l2), 2.56 (q, J = 8.0Hz, 2H, 5-CH 2CH3), 3.82 (s, 2H, CH 2Ph), 5.07-5.28 (m, 1H, OCH), 7.20-7.35 (m, 5H, Ph).
Compound3v
A: 1-hydroxybutane (50 ml); C: K (0.1); D: 3s (10); E: 240; F: 8i0 2, EtOAc/CHCb 1:1; G: 40; H: n-hexane; I: 70-71; J: C17H22N202 (286.36); K: 1630,3400; L: (CDCI 3 ) 0.90 (t, 3H, (CH 2hCH3), 1.03(t, 3H, 5-CH 2CH3), 1.27-1.67 (m, 4H, CH 2(CH2l2CH3 ) , 2.57 (q, 2H, 5-CH 2CH3), 3.87 (s, 2H, CH 2Ph), 4.23-4.37 (rn, 2H, OCH 2), 7.23-7.33 (m, 5H, Ph).
Preparation of compounds 4a,b
A solution of 3a (4.6 mmoles, 1.0g) in a mixture of CH 30H/H20 1:1 (100 ml) was treated with 96% sulphuric acid (11.11 ml) and the solution was refluxed for 24h. After cooling, the alcohol was removed under reduced pressure, the resulting solution was diluted with H20 (100ml), made basic with saturated solution of NaHC0 3 and extracted with EtOAc (3 x 50ml). The collected extracts were dried and evaporated to give 4a: yield 85%; mp 262-263°C (EtOH); IR (crrr") 1635, 1730; 1H NMR (DMF-d 7)
3.80 (s, 2H, CH2Ph), 5.30 (s, 1H, 5-H), 7.37 (m, 5H, Ph), 10.83 (s, 2H, NH exch. with D 20) .
A similar method was used starting with 3k to prepare 4b: yield 79%; mp 255-25rC (EtOH); IR (cm ") 1630, 1720; 1H NMR (DMF-d 7) 1.83 (s, 3H, 5-CH 3 ) , 3.88 (s, 2H, CH 2Ph), 7.33 (m, 5H, Ph), 10.80 (s, 2H, NH exch. with D 20) .
Anti-HIVassays
Activity of the compounds against HIV-1 (HTLV-IIIB) and HIV-2 (LAV-2 ROD) multiplication in acutely infected cells was based on the inhibition of virus-induced cytopathogenicity in MT-4 cells.
Briefly, 501-'-1 of culture medium containing 1 x 10 4 MT-4 cells were added to each well of flat-bottomed microtitre trays containing 501-'-1 of culture medium with or without various concentrations of the test compounds. Then 201-'-1 of an HIV-1 or HIV-2 suspension containing 100 CCID so (50% cell culture infective dose) were added. After a 4-day incubation at 3rC, the number of viable MT -4 cells was determined by the 3-(4,5-dimethylthiazol-1-yl)-2,5-diphenyltetrazolium bromide (MTl) method (Pauwels et al., 1988) . Cytotoxicity of the compounds was evaluated in parallel with their antiviral activity. It was based on the viability of mock-infected cells, as monitored by the MTT method.
The anti-HIV activity in chronically infected H9/111B cells was examined by measuring the infectious virus titre in C8166 cells as previously described (Botta et al., 1992) .
